A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function after Kidney Transplantation.
Datos básicos
Documentos
- No hay documentos
Grupos
Financiadores - Promotores
ALEXION PHARMACEUTICALS, INC.
Cita
A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function after Kidney Transplantation. (ALXN1210-DGF-321). ALEXION PHARMACEUTICALS, INC. 2025IP:JORDI ESPÍ REIG.
Portal de investigación